PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 77 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.36 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $9,218,000 | -66.2% | 1,092,212 | -45.4% | 0.01% | -53.8% |
| Q1 2022 | $27,238,000 | -24.8% | 2,001,442 | +8.7% | 0.01% | -13.3% |
| Q4 2021 | $36,218,000 | -42.1% | 1,841,357 | -5.5% | 0.02% | -44.4% |
| Q3 2021 | $62,531,000 | -5.4% | 1,948,002 | -0.2% | 0.03% | -3.6% |
| Q2 2021 | $66,067,000 | -10.0% | 1,951,634 | -0.1% | 0.03% | -17.6% |
| Q1 2021 | $73,414,000 | +14.0% | 1,954,448 | +0.8% | 0.03% | +13.3% |
| Q4 2020 | $64,396,000 | +11.9% | 1,938,436 | +23.6% | 0.03% | 0.0% |
| Q3 2020 | $57,538,000 | +10.8% | 1,568,796 | -0.6% | 0.03% | +3.4% |
| Q2 2020 | $51,951,000 | +23.2% | 1,578,679 | -5.3% | 0.03% | 0.0% |
| Q1 2020 | $42,175,000 | -3.2% | 1,667,577 | +13.6% | 0.03% | +31.8% |
| Q4 2019 | $43,589,000 | – | 1,467,462 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |